Pharming announces completion of acquisition of all North American commercialisation rights for RUCONEST® from Valeant
Pharming Group N.V. today announces that it has completed a definitive agreement to acquire all North American commercialisation rights for its own product, RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from certain subsidiaries of Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).
RUCONEST® is an orphan drug designated therapy developed by Pharming, already approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in the US and EU. This transaction will accelerate Pharming’s development into a profitable specialty pharmaceutical company with its own independent commercial infrastructure, which will form the foundation for future growth.
“This is a quantum leap forward for Pharming and marks a significant step for the Company taking control of its own destiny and providing a real prospect of reaching profitability soon."- Sijmen de Vries - CEO
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.